Cargando…

CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma

BACKGROUND: Cancer stem cells (CSCs) are at the origin of tumour initiation and progression in gastric adenocarcinoma (GC). However, markers of metastasis-initiating cells remain unidentified in GC. In this study, we characterized CD44 variants expressed in GC and evaluated the tumorigenic and metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraud, Julie, Seeneevassen, Lornella, Rousseau, Benoit, Bouriez, Damien, Sifré, Elodie, Giese, Alban, Nguyen, Tra Ly, Tiffon, Camille, Lippi, Yannick, Azzi-Martin, Lamia, Pannequin, Julie, Ménard, Armelle, Bessède, Emilie, Staedel, Cathy, Mégraud, Francis, Belleannée, Geneviève, Lehours, Philippe, Gronnier, Caroline, Dubus, Pierre, Varon, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950191/
https://www.ncbi.nlm.nih.gov/pubmed/36528833
http://dx.doi.org/10.1007/s10120-022-01357-y
_version_ 1784893110591946752
author Giraud, Julie
Seeneevassen, Lornella
Rousseau, Benoit
Bouriez, Damien
Sifré, Elodie
Giese, Alban
Nguyen, Tra Ly
Tiffon, Camille
Lippi, Yannick
Azzi-Martin, Lamia
Pannequin, Julie
Ménard, Armelle
Bessède, Emilie
Staedel, Cathy
Mégraud, Francis
Belleannée, Geneviève
Lehours, Philippe
Gronnier, Caroline
Dubus, Pierre
Varon, Christine
author_facet Giraud, Julie
Seeneevassen, Lornella
Rousseau, Benoit
Bouriez, Damien
Sifré, Elodie
Giese, Alban
Nguyen, Tra Ly
Tiffon, Camille
Lippi, Yannick
Azzi-Martin, Lamia
Pannequin, Julie
Ménard, Armelle
Bessède, Emilie
Staedel, Cathy
Mégraud, Francis
Belleannée, Geneviève
Lehours, Philippe
Gronnier, Caroline
Dubus, Pierre
Varon, Christine
author_sort Giraud, Julie
collection PubMed
description BACKGROUND: Cancer stem cells (CSCs) are at the origin of tumour initiation and progression in gastric adenocarcinoma (GC). However, markers of metastasis-initiating cells remain unidentified in GC. In this study, we characterized CD44 variants expressed in GC and evaluated the tumorigenic and metastatic properties of CD44v3+ cells and their clinical significance in GC patients. METHODS: Using GC cell lines and patient-derived xenografts, we evaluated CD44+ and CD44v3+ GC cells molecular signature and their tumorigenic, chemoresistance, invasive and metastatic properties, and expression in patients-derived tissues. RESULTS: CD44v3+ cells, which represented a subpopulation of CD44+ cells, were detected in advanced preneoplastic lesions and presented CSCs chemoresistance and tumorigenic properties in vitro and in vivo. Molecular and functional analyses revealed two subpopulations of gastric CSCs: CD44v3+ CSCs with an epithelial-mesenchymal transition (EMT)-like signature, and CD44+/v3– CSCs with an epithelial-like signature; both were tumorigenic but CD44v3+ cells showed higher invasive and metastatic properties in vivo. CD44v3+ cells detected in the primary tumours of GC patients were associated with a worse prognosis. CONCLUSION: CD44v3 is a marker of a subpopulation of CSCs with metastatic properties in GC. The identification of metastasis-initiating cells in GC represents a major advance for further development of anti-metastatic therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-022-01357-y.
format Online
Article
Text
id pubmed-9950191
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-99501912023-02-25 CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma Giraud, Julie Seeneevassen, Lornella Rousseau, Benoit Bouriez, Damien Sifré, Elodie Giese, Alban Nguyen, Tra Ly Tiffon, Camille Lippi, Yannick Azzi-Martin, Lamia Pannequin, Julie Ménard, Armelle Bessède, Emilie Staedel, Cathy Mégraud, Francis Belleannée, Geneviève Lehours, Philippe Gronnier, Caroline Dubus, Pierre Varon, Christine Gastric Cancer Original Article BACKGROUND: Cancer stem cells (CSCs) are at the origin of tumour initiation and progression in gastric adenocarcinoma (GC). However, markers of metastasis-initiating cells remain unidentified in GC. In this study, we characterized CD44 variants expressed in GC and evaluated the tumorigenic and metastatic properties of CD44v3+ cells and their clinical significance in GC patients. METHODS: Using GC cell lines and patient-derived xenografts, we evaluated CD44+ and CD44v3+ GC cells molecular signature and their tumorigenic, chemoresistance, invasive and metastatic properties, and expression in patients-derived tissues. RESULTS: CD44v3+ cells, which represented a subpopulation of CD44+ cells, were detected in advanced preneoplastic lesions and presented CSCs chemoresistance and tumorigenic properties in vitro and in vivo. Molecular and functional analyses revealed two subpopulations of gastric CSCs: CD44v3+ CSCs with an epithelial-mesenchymal transition (EMT)-like signature, and CD44+/v3– CSCs with an epithelial-like signature; both were tumorigenic but CD44v3+ cells showed higher invasive and metastatic properties in vivo. CD44v3+ cells detected in the primary tumours of GC patients were associated with a worse prognosis. CONCLUSION: CD44v3 is a marker of a subpopulation of CSCs with metastatic properties in GC. The identification of metastasis-initiating cells in GC represents a major advance for further development of anti-metastatic therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-022-01357-y. Springer Nature Singapore 2022-12-18 2023 /pmc/articles/PMC9950191/ /pubmed/36528833 http://dx.doi.org/10.1007/s10120-022-01357-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Giraud, Julie
Seeneevassen, Lornella
Rousseau, Benoit
Bouriez, Damien
Sifré, Elodie
Giese, Alban
Nguyen, Tra Ly
Tiffon, Camille
Lippi, Yannick
Azzi-Martin, Lamia
Pannequin, Julie
Ménard, Armelle
Bessède, Emilie
Staedel, Cathy
Mégraud, Francis
Belleannée, Geneviève
Lehours, Philippe
Gronnier, Caroline
Dubus, Pierre
Varon, Christine
CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
title CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
title_full CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
title_fullStr CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
title_full_unstemmed CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
title_short CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
title_sort cd44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950191/
https://www.ncbi.nlm.nih.gov/pubmed/36528833
http://dx.doi.org/10.1007/s10120-022-01357-y
work_keys_str_mv AT giraudjulie cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT seeneevassenlornella cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT rousseaubenoit cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT bouriezdamien cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT sifreelodie cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT giesealban cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT nguyentraly cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT tiffoncamille cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT lippiyannick cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT azzimartinlamia cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT pannequinjulie cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT menardarmelle cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT bessedeemilie cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT staedelcathy cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT megraudfrancis cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT belleanneegenevieve cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT lehoursphilippe cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT gronniercaroline cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT dubuspierre cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma
AT varonchristine cd44v3isamarkerofinvasivecancerstemcellsdrivingmetastasisingastriccarcinoma